sureprint g3 human cgh microarray kit, 8×60k g4450a (Agilent technologies)
Agilent technologies is a verified supplier 
Agilent technologies manufactures this product 
90
Structured Review
Agilent technologies
sureprint g3 human cgh microarray kit, 8×60k g4450a
Sureprint G3 Human Cgh Microarray Kit, 8×60k G4450a, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sureprint+g3+human+cgh+microarray+kit/pm38814455-46-25-27
Average 90 stars, based on 1 article reviews
Sureprint G3 Human Cgh Microarray Kit, 8×60k G4450a, supplied by Agilent technologies, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/sureprint+g3+human+cgh+microarray+kit/pm38814455-46-25-27
Average 90 stars, based on 1 article reviews
sureprint g3 human cgh microarray kit, 8×60k g4450a - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
Microarray:Article Title: Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network Article Snippet: Tumor DNA was extracted from FFPE blocks or hematoxylin–eosin–safran (HES) slides by automated methods using the EZ-1 tissue kit, QIAGEN™, according to the manufacturer’s instructions. .. The cases with DNA of sufficient quality (determined on Agilent Bioanalyzer (Agilent Technologies, Massy, France)) were analysed as previously described [ ] using high-resolution 4 × 180 K CGH microarrays ( Article Title: Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network. Article Snippet: Tumor DNA was extracted from FFPE blocks or hematoxylin–eosin–safran (HES) slides by automated methods using the EZ-1 tissue kit, QIAGEN™, according to the manufacturer’s instructions. .. The cases with DNA of sufficient quality (determined on Agilent Bioanalyzer (Agilent Technologies, Massy, France)) were analysed as previously described [22] using high-resolution 4 × 180 K CGH microarrays ( Article Title: Hyaline Cartilage Microtissues Engineered from Adult Dedifferentiated Chondrocytes: Safety and Role of WNT Signaling Article Snippet: DNA was extracted using the QIAGEN QIAamp DNA Mini Kit (Qiagen, Hilden) according to the manufacturer’s protocol. .. Array CGH was performed using the Agilent Article Title: Genome-wide study of copy number variation implicates multiple novel loci for schizophrenia risk in Han Chinese family trios Article Snippet: QIAamp DNA blood Kits , Qiagen , Cat#51104. .. Article Title: Prospective high-throughput genome profiling of advanced cancers: results of the PERMED-01 clinical trial Article Snippet: .. Briefly, aCGH was done onto high-resolution 4 × 180 K CGH microarrays ( Article Title: Overcoming Resistance to Anti–Nectin-4 Antibody-Drug Conjugate Article Snippet: TumorDNAswere extracted from sensitive and resistant preclinical models (14) and controlled on Agilent Bioanalyzer. .. Genomic profiles of samples were established by using array-CGH onto 4 180K CGH microarrays ( Article Title: Molecular Profiles of Advanced Urological Cancers in the PERMED-01 Precision Medicine Clinical Trial Article Snippet: .. Array-CGH experiments were done using high-resolution microarrays ( Article Title: Increased nuchal translucency with normal karyotype and genomic microarray analysis: A multicenter observational study. Article Snippet: Nuchal translucency (NT) is a physiologic retronuchal collection of fluid that can be identified in all fetuses in the first trimester of pregnancy.. NT can be increased in several fetal pathologic conditions such as cardiac congenital anomalies, chromosomal abnormalities and genetic disorders; for this reason, NT of 3.5 mm or more (≥99th centile for all gestational ages) requires genetic and ultrasound investigations, including fetal echocardiography.. The incidence of fetal structural abnormalities and genetic/ chromosomal disorders increases from 30% for NT between 3.5 and 4.5 mm to approximately 70% for NT greater than 6.5 mm.1 Received: 17 August 2022 | Revised: 28 November 2022 | Accepted: 9 December 2022 | Published online: 17 January 2023 DOI: 10.1002/ijgo.14637 |